SUBSCRIBE
SUBSCRIBE
News   Business

AstraZeneca PLC to Further Develop Targacept, Inc.'s ADHD Drug; Targacept Eligible to Get Over $100 Million

July 8, 2009 | 
1 min read
Bookmark and Share

Reuters -- Targacept Inc said its licensing partner AstraZeneca agreed to pay $10 million milestone payment to further develop Targacept's experimental treatment for attention deficit/hyperactivity disorder (ADHD).
Alliances
AstraZeneca
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Gilead laying off vast majority of Arcellx employees
May 8, 2026
 · 
51 min read
 · 
BioSpace Editorial Staff
3d render of the pole vault crossbar on blue sky background
Earnings
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
May 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.
Pipeline
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
May 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Composite photo collage of hand hold magnifier glass research examine secret object question mark secret isolated on painted background.
Manufacturing
FDA pilots AI-informed one-day facility inspections
May 7, 2026
 · 
2 min read
 · 
Nick Paul Taylor